Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASH 2019 | The Moffit experience of lenalidomide and rituximab for MCL

Bijal Shah • 10 Dec 2019
ASH 2019
B-Cell Lymphoma Lymphoma Mantle Cell Lymphoma Non-Hodgkin Lymphoma Lenalidomide Rituximab

Bijal Shah, MD, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, outlines the Moffitt experience of lenalidomide plus rituximab in TP53-mutated mantle cell lymphoma (MCL) outside of the clinical trial setting. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Bijal Shah

The potential value of early integration of CAR-T in ALL 1:44
The potential value of early integration of CAR-T in ALL
Bijal Shah • 4 Sep 2025
Exploring strategies to optimize post-CAR-T outcomes in patients with ALL 1:15
Exploring strategies to optimize post-CAR-T outcomes in patients with ALL
Bijal Shah • 4 Sep 2025
Moving next-generation CAR constructs into ALL therapy 2:11
Moving next-generation CAR constructs into ALL therapy
Bijal Shah • 4 Sep 2025
The current role of CAR T-cell therapy in high-risk B-ALL 1:20
The current role of CAR T-cell therapy in high-risk B-ALL
Bijal Shah • 4 Sep 2025

Related Videos

Preliminary findings from a trial of a novel CD30-directed antibody-drug conjugate in R/R lymphomas 1:57
Preliminary findings from a trial of a novel CD30-directed antibody-drug conjugate in R/R lymphomas
Swetha Thiruvengadam • 8 Dec 2025
Interim analysis of a Phase II trial of epcoritamab plus lenalidomide in treatment-naive FL 1:14
Interim analysis of a Phase II trial of epcoritamab plus lenalidomide in treatment-naive FL
Swetha Thiruvengadam • 8 Dec 2025
Primary Phase III results from the EPCORE FL-1 trial: epcoritamab plus R2 versus R2 for R/R FL 3:07
Primary Phase III results from the EPCORE FL-1 trial: epcoritamab plus R2 versus R2 for R/R FL
Lorenzo Falchi • 6 Dec 2025
Phase II trial of mosunetuzumab with response-driven lenalidomide augmentation in FL and MZL 3:05
Phase II trial of mosunetuzumab with response-driven lenalidomide augmentation in FL and MZL
Adam Olszewski • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals